Intrathymic selection: New insight into tumor immunology

Advances in Experimental Medicine and Biology

Volumn 601, Issue , 2007, Pages 133-144

  Kazansky, Dmitry B ^a  

^a N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; TUMOR ANTIGEN;

ANIMAL; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BIOLOGICAL MODEL; CHEMISTRY; CYTOLOGY; EPITHELIUM CELL; GENETIC EPIGENESIS; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; METABOLISM; METHODOLOGY; NEOPLASM; PROTEIN MOTIF; REVIEW; THYMUS;

AMINO ACID MOTIFS; ANIMALS; ANTIGENS; ANTIGENS, NEOPLASM; AUTOIMMUNE DISEASES; AUTOIMMUNITY; EPIGENESIS, GENETIC; EPITHELIAL CELLS; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; MODELS, BIOLOGICAL; NEOPLASMS; THYMUS GLAND;

EID: 34848859957     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-72005-0_14     Document Type: Conference Paper

References (54)

1. Amrolia, P.J., Reid, S.D., Gao, L., Schultheis, B., Dotti, G., Brenner, M.K., Melo, J.V., Goldman, J.M. and Stauss, H.J. (2003) Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity. Blood 101, 1007-1014.
2. Anderson, M.S., Venanzi, E.S., Chen, Z., Berzins, S.P., Benoist, C. and Mathis, D. (2005) The cellular mechanism of Aire control of T cell tolerance. Immunity 23, 227-239.
3. Brandle, D., Brasseur, F., Weynants, P., Boon, T. and Van Den Eynde, B. (1996) A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J. Exp. Med. 183, 2501-2508.
4. Cerundolo, V., Elliott, T., Elvin, J., Bastin, J., Rammensee, H.G. and Townsend, A. (1991) The binding affinity and dissociation rates of peptides for class I major histocompatibility complex molecules. Eur. J. Immunol. 21, 2069-2075.
5. Cohen, C.J., Zhao, Y., Zheng, Z., Rosenberg, S.A. and Morgan, R.A. (2006) Enhanced antitumor activity of murine-human hybrid T cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 66, 8878-8886.
6. Coulie, P.G., Lehmann, F., Lethe, B., Herman, J., Lurquin, C., Andrawiss, M. and Boon, T. (1995) A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl. Acad. Sci. U.S.A. 92, 7976-7980.
7. Dubey, P., Hendrickson, R.C., Meredith, S.C., Siegel, C.T., Shabanowitz, J., Skipper, J.C., Engelhard, V.H., Hunt, D.F. and Schreiber, H. (1997) The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68. J. Exp. Med. 185, 695-705.
8. Egger, G., Liang, G., Aparicio, A. and Jones, P.A. (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429, 457-463.
9. Falk, K., Rotzschke, O. Stevanovic, S., Jung, G. and Rammensee, H.G. (1991a) Allelespecific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351, 290-296.
10. Falk, K., Rotzschke, O., Deres, K., Metzger, J., Jung, G. and Rammensee, H.G. (1991b) Identification of naturally processed viral nonapeptides allows their quantification in infected cells and suggests an allele-specific T cell epitope forecast. J. Exp. Med. 174, 425-434.
11. Falk, K., Rotzschke, O. and Rammensee, H.G. (1990) Cellular peptide composition governed by major histocompatibility complex class I molecules. Nature 348, 248-251.
12. Felsher, D.W. (2003) Cancer revoked: Oncogenes as therapeutic targets. Nat. Rev. Cancer 3, 375-380.
13. Gao, L., Bellantuono, I., Elsasser, A., Marley, S.B., Gordon, M.Y., Goldman, J.M. and Stauss, H.J. (2000) Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95, 2198-2203.
14. Golovkina, T.V., Chervonsky, A., Dudley, J.P. and Ross, S.R. (1992) Transgenic mouse mammary tumor virus superantigen expression prevents viral infection. Cell 69, 637-645.
15. Hahn, W.C. and Weinberg, R.A. (2002) Rules for making human tumor cells. N. Engl. J. Med. 347, 1593-1603.
16. Kalbus, M., Fleckenstein, B.T., Offenhausser, M., Bluggel, M., Melms, A., Meyer, H.E., Rammensee, H.G., Martin, R., Jung, G. and Sommer, N. (2001) Ligand motif of the autoimmune disease-associated mouse MHC class II molecule H2-As. Eur. J. Immunol. 31, 551-562.
17. Li, E. (2002) Chromatin modification and epigenetic reprogramming in mammalian development. Nat. Rev. Genet. 3, 662-673.
18. Logunova, N.N., Viret, C., Pobezinsky, L.A., Miller, S.A., Kazansky, D.B., Sundberg, J.P. and Chervonsky, A.V. (2005) Restricted MHC-peptide repertoire predisposes to autoimmunity. J. Exp. Med. 202, 73-84.
19. Monach, P.A., Meredith, S.C., Siegel, C.T. and Schreiber, H. (1995) A unique tumor antigen produced by a single amino acid substitution. Immunity 2, 45-59.
20. Morris, E.C., Tsallios, A., Bendle, G.M., Xue, S.A. and Stauss, H.J. (2005) A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection. Proc. Natl. Acad. Sci. U.S.A. 102, 7934-7939.
21. Munz, C., Hofmann, M., Yoshida, K., Moustakas, A.K., Kikutani, H., Stevanovic, S., Papadopoulos, G.K. and Rammensee, H.G. (2002) Peptide analysis, stability studies, and structural modeling explain contradictory peptide motifs and unique properties of the NOD mouse MHC class II molecule H2-Ag7. Eur. J. Immunol. 32, 2105-2116.
22. Pelleitier, M. and Montplaisir, S. (1975) The nude mouse: A model of deficient T cell function. Methods Achiev. Exp. Pathol. 7, 149-166.
23. Pobezinskaya, Y., Chervonsky, A.V. and Golovkina, T.V. (2004) Initial stages of mammary tumor virus infection are superantigen independent. J. Immunol. 172, 5582-5587.
24. Prehn, R.T. (2005) On the nature of cancer and why anticancer vaccines don't work. Cancer Cell Int. 5, 25.
25. Prehn, R.T. and Main, J.M. (1957) Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst. 18, 769-778.
26. Rammensee, H.G. (1995) Chemistry of peptides associated with MHC class I and class II molecules. Curr. Opin. Immunol. 7, 85-96.
27. Rammensee, H.G., Falk, K. and Rotzschke, O. (1993) Peptides naturally presented by MHC class I molecules. Annu. Rev. Immunol. 11, 213-244.
28. Reche, P.A., Glutting, J.P., Zhang, H. and Reinherz, E.L. (2004) Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles. Immunogenetics 56, 405-419.
29. Robbins, P.F., El-Gamil, M., Li, Y.F., Kawakami, Y., Loftus, D., Appella, E. and Rosenberg, S.A. (1996) A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183, 1185-1192.
30. Rosenberg, S.A., Sherry, R.M., Morton, K.E., Scharfman, W.J., Yang, J.C., Topalian, S.L., Royal, R.E., Kammula, U., Restifo, N.P., Hughes, M.S., Schwartzentruber, D., Berman, D.M., Schwarz, S.L., Ngo, L.T., Mavroukakis, S.A., White, D.E. and Steinberg, S.M. (2005) Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J. Immunol. 175, 6169-6176.
31. Rotzschke, O., Falk, K., Deres, K., Schild, H., Norda, M., Metzger, J., Jung, G. and Rammensee, H.G. (1990) Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature 348, 252-254.
32. Rotzschke, O., Falk, K., Stevanovic, S., Jung, G., Walden, P. and Rammensee, H.G. (1991) Exact prediction of a natural T cell epitope. Eur. J. Immunol. 21, 2891-2894.
33. Sadovnikova, E., Jopling, L.A., Soo, K.S. and Stauss, H.J. (1998) Generation of human tumorreactive cytotoxic T cells against peptides presented by non-self HLA class I molecules. Eur. J. Immunol. 28, 193-200.
34. Sadovnikova, E. and Stauss, H.J. (1996) Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: Reagents for tumor immunotherapy. Proc. Natl. Acad. Sci. U.S.A. 93, 13114-13118.
35. Sadovnikova, E., Parovichnikova, E.N., Savchenko, V.G., Zabotina, T. and Stauss, H.J. (2002) The CD68 protein as a potential target for leukaemia-reactive CTL. Leukemia 16, 2019-2026.
36. Sharkey, F.E. and Fogh, J. (1979) Incidence and pathological features of spontaneous tumors in athymic nude mice. Cancer Res. 39, 833-839.
37. Sherman, L.A., Theobald, M., Morgan, D., Hernandez, J., Bacik, I., Yewdell, J., Bennink, J. and Biggs, J. (1998) Strategies for tumor elimination by cytotoxic T lymphocytes. Crit. Rev. Immunol. 18, 47-54.
38. Simpson, A.J., Caballero, O.L., Jungbluth, A., Chen, Y.T. and Old, L.J. (2005) Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer 5, 615-625.
39. Sommermeyer, D., Neudorfer, J., Weinhold, M., Leisegang, M., Engels, B., Noessner, E., Heemskerk, M.H., Charo, J., Schendel, D.J., Blankenstein, T., Bernhard, H. and Uckert, W. (2006) Designer T cells by T cell receptor replacement. Eur. J. Immunol. 36, 3052-3059.
40. Su, M.A. and Anderson, M.S. (2004) Aire: An update. Curr. Opin. Immunol. 16, 746-752.
41. Svane, I.M., Boesen, M. and Engel, A.M. (1999) The role of cytotoxic T lymphocytes in the prevention and immune surveillance of tumors - lessons from normal and immunodeficient mice. Med. Oncol. 16, 223-238.
42. Svane, I.M., Engel, A.M., Nielsen, M.B., Ljunggren, H.G., Rygaard, J. and Werdelin, O. (1996) Chemically induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic normal mice. Eur. J. Immunol. 26, 1844-1850.
43. Van Der Bruggen, P., Zhang, Y., Chaux, P., Stroobant, V., Panichelli, C., Schultz, E.S., Chapiro, J., Van Den Eynde, B.J., Brasseur, F. and Boon, T. (2002) Tumor-specific shared antigenic peptides recognized by human T cells. Immunol. Rev. 188, 51-64.
44. Vartdal, F., Johansen, B.H., Friede, T., Thorpe, C.J., Stevanovic, S., Eriksen, J.E., Sletten, K., Thorsby, E., Rammensee, H.G. and Sollid, L.M. (1996) The peptide binding motif of the disease associated HLA-DQ (alpha 1 0501, beta 1 0201) molecule. Eur. J. Immunol. 26, 2764-2772.
45. Wallny, H.J., Deres, K., Faath, S., Jung, G., Van Pel, A., Boon, T. and Rammensee, H.G. (1992b) Identification and quantification of a naturally presented peptide as recognized by cytotoxic T lymphocytes specific for an immunogenic tumor variant. Int. Immunol. 4, 1085-1090.
46. Wallny, H.J., Rotzschke, O., Falk, K., Hammerling, G. and Rammensee, H.G. (1992a) Gene transfer experiments imply instructive role of major histocompatibility complex class I molecules in cellular peptide processing. Eur. J. Immunol. 22, 655-659.
47. Ward, P.L., Koeppen, H.K., Hurteau, T., Rowley, D.A. and Schreiber, H. (1990) Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T cell-dependent surveillance. Cancer Res. 50, 3851-3858.
48. Willemsen, R.A., Debets, R., Chames, P. and Bolhuis, R.L. (2003) Genetic engineering of T cell specificity for immunotherapy of cancer. Hum. Immunol. 64, 56-68.
49. Wilson, D.B., Wilson, D.H., Schroder, K., Pinilla, C., Blondelle, S., Houghten, R.A. and Garcia, K.C. (2004) Specificity and degeneracy of T cells. Mol. Immunol. 40, 1047-1055.
50. Wolfel, T., Hauer, M., Schneider, J., Serrano, M., Wolfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Buschenfelde, K.H. and Beach, D. (1995) A p16INK4ainsensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269, 1281-1284.
51. Woodruff, M.F. and Hodson, B.A. (1985) The effect of passage in vitro and in vivo on the properties of murine fibrosarcomas I. Tumorigenicity and immunogenicity. Br. J. Cancer 51, 161-169.
52. Xu, X.N. and Screaton, G.R. (2002) MHC/peptide tetramer-based studies of T cell function. J. Immunol. Methods 268, 21-28.
53. Xue, S., Gillmore, R., Downs, A., Tsallios, A., Holler, A., Gao, L., Wong, V., Morris, E. and Stauss, H.J. (2005) Exploiting T cell receptor genes for cancer immunotherapy. Clin. Exp. Immunol. 139, 167-172.
54. Zerrahn, J., Held, W. and Raulet, D.H. (1997) The MHC reactivity of the T cell repertoire prior to positive and negative selection. Cell 88, 627-636.